

**Clinical and biological characteristics of SCLC patients analyzed for the survival study
(Extended Data Fig. 9)**

Patient characteristics (n=73)	Variables: % (n); median [interquartile range]
Sex	
Male	61.6% (45)
Female	38.4% (28)
Median age at diagnosis (years)	63.5 [58.2-73.1]
Tobacco status	
Non-smoker	1.4% (1)
Former smoker	1.4% (1)
Active smoker	97.3% (71)
Histology type	
Pure SCLC	83.6% (61)
Mixed SCLC	16.4% (12)
Biopsy (primary tumor)	
Bronchial biopsy	83.6% (61)
Lung CT-guided core biopsy / surgical biopsy	16.4% (12)
TNM staging	
I	12.3% (19)
II	5.5% (4)
III	21.9% (16)
IV	60.3% (44)
First treatment	
Surgery	9.6% (7)
Chemo-radiotherapy	8.2% (6)
Chemotherapy	76.7% (56)
No treatment	5.5% (4)
Response of first treatment <i>(only evaluated for patients treated with chemo-radiotherapy or chemotherapy)</i>	
Complete response	11.3% (7)
Partial response	41.9% (26)
Stable disease	6.5% (4)
Progressive disease	40.3% (25)
Survival (months)	
Progression-free survival	7 [3-11]
Overall survival	13 [5-22]

Primers (against murine sequences, unless otherwise stated) used for qRT-PCR

Gene	Forward primer (5'-3')	Reverse primer 5'-3'
Ascl1	GCTCTCCTGGGAATGGACT	CGTTGGCGAGAAACACTAAAG
Calca	TGCAGGACTATATGCAGATGAAA	GGATCTCTTCTGAGCAGTGACA
ChgA	CGATCCAGAAAGATGATGGTC	CGGAAGCCTCTGTCTTTCC
ChgB	CCTCTCAAATGCCCTATCCA	CACCTTTGACCTCTTTTTCCACT
Ddc	CACAGAAGTCATTCTTGGGTTG	GAGTTTCGTTCAACTCATTGGA
Dll1	GGGACAGAGGGGAGAAGATG	TCCATGTTGGTCATCACACC
Dll3	TCGTACGTGTGCCCTTCC	TGCTCTCTCCAGGTTTCAATG
Dll4	AGGTGCCACTTCGGTTACAC	GGGAGAGCAAATGGCTGATA
GAPDH (human)	AGCCACATCGCTCAGACAC	GCCCAATACGACCAAATCC
GFP	ACTACAACAGCCACAACGTCT ATATCA	GGCGGATCTTGAAGTTCACC
Hes1	TGCCAGCTGATATAATGGAGAA	CCATGATAGGCTTTGATGACTTT
HES1 (human)	GAAGCACCTCCGGAACCT	GTCACCTCGTTCATGCACTC
Hey1	CATGAAGAGAGCTCACCCAGA	CGCCGAACTCAAGTTTCC
Hey2	GTGGGGAGCGAGAACAATTA	GTTGTGCGGTGAATTGGACCT
Jag1	TGGCCGAGGTCCTACACTT	GCCTTTTCAATTATGCTATCAGG
Jag2	TCCTCCTGCTGCTTTGTGAT	TTGCAGGGCTGAAAGACAC
Notch1	CGCCCGTGGATTCATCTGTA	AAGTGCGGGCATCATTCTCA
Notch2	TGCCTGTTTGACAACTTTGAGT	GTGGTCTGCACAGTATTTGTCAT
Notch3	GGAGCCTGTGGGACAAGAT	CTCCCCCATCAGACTCTCAC
Nrarp	GCTACACATCGCCGCTTT	TTGGCCTTGGTGATGAGATA
Rest	GACTCATCTAACGCGACACATGCG	GCGTAGTCACACACGGGGCAGTTGAAC
Rplp0	GATGCCCAGGGAAGACAG	ACAATGAAGCATTTTGGATAATCA
Syp	CTGGCAGACATGGACGTG	CTTGACCACCCGGAAGTCTG

Genotyping primers for unrecombined and recombined *Rb*, *p53* and *p130* floxed alleles

Gene	Forward primer (5'-3')	Allele	Reverse primer (5'-3')	Size (bp)
Rb	CTCTAGATCCTCTCATTCTTCCC	floxed	CCTTGACCATAGCCCAGCAC	308
		delta	GCAGGAGGCAAAAATCCACATAAC	700
p53	CGCAATCCTTTATTCTGTTCG	floxed	AGCACATAGGAGGCAGAGAC	212
		delta	TGAGACAGGGTCTTGCTATTG	168
p130	GTGTTGTAACATTCTCATGGG	floxed	CCTCAATCCCATGGTGGTG	278
		delta	CATCCCCTCCTATGAACATAC	450

Primers for ChIP-qPCR

Gene	Forward primer (5'-3')	Reverse primer 5'-3'
Ascl1	AGCTGAATGGAACAGCAGTGGCAA	CCCTTTCTTCTCTCCGCAGTAACT
Calca	CTCCCAGGCTACAAGTCCTTC	AGCCATCCTCCTTTTAGGCTG
ChgA	AGGAGTCCCAGACAGGATGA	AGACCGCTACTAGGCTCAGA
ChgB	CGGTGAGTGGGATTCAGCA	AGGCAAGGCAAGGGATACAG
Hes1	CGTGTCTCTTCCCTCCATTG	CCAGGACCAAGGAGAGAGGT
m5VE	GGGGATAATGATTGCAAAA	GCGTGGACAGAGATCTAGGC
mNC6	GCTCCCTCAGCTTCAACATC	CAGAGTGATGAAAGGGTGGA
Rest	CTCCGCCTCGGGCCCAACG	GCCTTCCGGCCCTGCTAC
Syp	ACATGGACGTGGTGAATCAGG	CCAGATTTCTGCAAGCGCC

Supplementary Figure 1 - Source data for immunoblots

